Helix Therapeutics
Operating Status: Inactive
Helix Therapeutics Inc. pioneers in DNA-based therapies for HIV/AIDS, sickle cell anemia, and cystic fibrosis in the US.
Founded
2006Helix Therapeutics Inc. pioneers in DNA-based therapies for HIV/AIDS, sickle cell anemia, and cystic fibrosis in the US.
Helix Therapeutics Inc. was founded with the mission to revolutionize the treatment of genetic disorders through DNA-based therapeutics. The company's vision is to provide innovative, sequence-specific gene-targeting treatments for diseases such as HIV/AIDS, sickle cell anemia, and cystic fibrosis. Helix Therapeutics focuses on serving patients and healthcare providers in the United States by developing cutting-edge therapies that address the root causes of these conditions.
Notable figures affiliated with Helix Therapeutics include leading researchers and scientists in the field of genetic therapy. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements include successful preclinical trials demonstrating the efficacy of their gene-targeting treatments. Overall, Helix Therapeutics has made a substantial impact by advancing the potential for curative therapies for chronic genetic diseases, aiming to improve patient outcomes and quality of life.
Companies similar to Helix Therapeutics include Helix BioMedix, Helicon Therapeutics, Helixbind and Gene Sciences.
Helix Therapeutics was founded in 2006.
Helix Therapeutics' headquarters is located in New Haven, CT, US.
Helix Therapeutics' most recent funding round was for $2.5M (USD) in November 2010.
As of Nov 23, 2010, Helix Therapeutics has disclosed funding of $3.4M (USD). Undisclosed round amounts are excluded.
Gene Sciences
